Geriatric and Palliative Care Specialists as Valued Members of the Multidisciplinary Heart Team - 16/06/22
Doi : 10.1016/j.amjmed.2022.01.020
Ashok Krishnaswami, MD, MAS a, b, c, ⁎ 
, Gwen M. Bernacki, MD d, e, f, Deepak L. Bhatt, MD, MPH g
, Gwen M. Bernacki, MD d, e, f, Deepak L. Bhatt, MD, MPH g a Section of Geriatric Medicine, Division of Primary Care and Population Health, Stanford University School of Medicine, Stanford, Calif
b Geriatric Research, Education and Clinical Center. US Department of Veterans Affairs, VA Palo Alto Health Care System, Palo Alto, Calif
c Division of Cardiology, Kaiser Permanente San Jose Medical Center, San Jose, Calif
d Division of Cardiology, University of Washington, Seattle
e Cambia Palliative Care Center of Excellence, University of Washington, Seattle
f Hospital and Specialty Medicine, Veterans Administration of Puget Sound, Seattle, Wash
g Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Mass
⁎Requests for reprints should be addressed to Ashok Krishnaswami, MD, MAS. Kaiser Permanente San Jose Medical Center, Division of Cardiology, 270 International Circle, Bulding 3, 2nd Floor, San Jose, CA 95119.Geriatric ResearchEducation and Clinical Center. U.S. Department of Veterans AffairsVA Palo Alto Health Care SystemPalo AltoCA
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflicts of Interest: AK, GMB report none. DLB reports serving on the advisory board for Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; serving on the board of directors for Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; serving as chair: Inaugural Chair, American Heart Association Quality Oversight Committee; serving on data monitoring committees for Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, and Population Health Research Institute; receiving honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); as well as affiliations with Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), and VA CART Research and Publications Committee (Chair); receiving research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, and 89Bio; receiving royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); serving as site coinvestigator for Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, and Svelte; and serving as a trustee for the American College of Cardiology; Unfunded Research: FlowCo, Merck, and Takeda. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
© 2022
Elsevier Inc. Tous droits réservés.
Vol 135 - N° 7
P. 810-812 - juillet 2022 Retour au numéro
Article précédent
- Cautious Optimism and Considerations for Health Providers and Patients: Oral Antiviral for Early Treatment of High-Risk Patients and Vaccines for Prevention of COVID-19
- Jennifer Caceres, Dennis G. Maki, Charles H. Hennekens
- Simplicity in Medicine: For a Return to Patient-Based Care
- Alain Putot
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?